Table 1 COVID-19 correlated repurposing drugs in clinical trials
From: A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives
Drug name | Original indication | New indication/remark | Clinical trial stage |
|---|---|---|---|
Chloroquine | In treatment for systemic lupus erythematosus and rheumatoid arthritis | Emergency approval for COVID-19 treatment revoked by FDA (June 2020)-withdrawn | Phase III |
Hydrochloroquine | In treatment for rheumathoid arthritis and Sjorgren’s syndrome | Emergency approval for COVID-19 treatment revoked by FDA(June 2020)-withdrawn | Phase III |
Ivermectin | For strongyloidiasis and onchocerciasis treatment | COVID-19 treatment | Phase III |
Interferon alfa (IFN-α) | Cancer immunotherapy | COVID-19 treatment | Phase II |
Fluvoxamine | In treatment for obsessive-compulsive disorder | COVID-19 treatment | Phase III |
Molnupiravir | Anti-viral drug | Emergency approval for COVID-19 treatment (December 2021)/UK Regulatory Agency approval | Phase III/clinical use |
Sofosbuvir | Chronic hepatitis C | COVID-19 treatment | Phase IV |
Ebselen | Demonstrating cytotoxicity against yeast, fungi, and bacteria | COVID-19 treatment | Phase II |
Favipiravir | Antiviral activity against influenza, yellow fever and ebola | Emergency approval for COVID-19 treatment (May, 2020) | Phase III/clinical use |
Ribavirin | Chronic hepatitis C infection | COVID-19 treatment | Phase II |
Remdesivir | Antiviral activity against paramyxoviruses, flaviviruses and coronaviruses. | COVID-19 treatment/FDA approved in October 2020 | Clinical use |